#nmibc
Latest news and interesting information about nmibc.
Oppenheimer Reiterates Outperform on UroGen Pharma
Oppenheimer reiterates Outperform on UroGen Pharma with $40 target. Strong commercial momentum for Zusduri driven by physician enthusiasm.
Truist raises CG Oncology target to $82 on NMIBC data
Truist Securities raises CG Oncology price target to $82 from $77 on NMIBC data. Stock near 52-week high after 206% yearly gain.
...